-
- Haoyu Xiong
- Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand
-
- Rakesh N. Veedu
- Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia
-
- Sarah D. Diermeier
- Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand
説明
<jats:p>Cancer is one of the leading causes of death worldwide. Conventional therapies, including surgery, radiation, and chemotherapy have achieved increased survival rates for many types of cancer over the past decades. However, cancer recurrence and/or metastasis to distant organs remain major challenges, resulting in a large, unmet clinical need. Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. While no approved oligonucleotide drug currently exists for any type of cancer, results obtained in preclinical studies and clinical trials are encouraging. Here, we provide an overview of recent developments in the field of oligonucleotide therapeutics in oncology, review current clinical trials, and discuss associated challenges.</jats:p>
収録刊行物
-
- International Journal of Molecular Sciences
-
International Journal of Molecular Sciences 22 (7), 3295-, 2021-03-24
MDPI AG
